AIM IMMUNOTECH INC. (AIM) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 4.95M USD | Liabilities, Current |
| Cash and equivalents | 9.90M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 64.00K USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $4.95M | $9.90M | $64.00K | (m) | (m) | (m) |
| 2026-03-31 | (m) | $6.14M | $5.82M | $63.00K | (m) | (m) | (m) |
| 2025-12-31 | $3.05M | $6.22M | $2.98M | $62.00K | $7.00K | (m) | 0.49× |
| 2025-09-30 | (m) | $4.04M | $2.35M | $62.00K | (m) | (m) | (m) |
| 2025-06-30 | (m) | $10.39M | $476.00K | $359.00K | (m) | (m) | (m) |
| 2025-03-31 | (m) | $9.77M | $898.00K | $1.35M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $9.54M | $1.70M | $2.28M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $10.10M | $915.00K | $6.29M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $8.84M | $3.55M | $6.51M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $9.88M | $3.29M | $7.65M | (m) | (m) | (m) |
| 2023-12-31 | $14.25M | $8.65M | $5.44M | $7.63M | $1.18M | (m) | 1.65× |
| 2023-09-30 | $22.48M | $4.72M | $15.26M | $7.17M | $48.00K | (m) | 4.77× |
| 2023-06-30 | $28.43M | $2.88M | $21.04M | $7.36M | $33.00K | (m) | 9.85× |
| 2023-03-31 | $32.61M | $1.84M | $23.39M | $7.45M | $1.76M | (m) | 17.75× |
| 2022-12-31 | (m) | $1.36M | $27.05M | $7.14M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $2.90M | $29.76M | $6.99M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $1.37M | $34.45M | $7.32M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $766.00K | $28.99M | $15.55M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $673.00K | $32.09M | $16.18M | (m) | (m) | (m) |
| 2021-09-30 | $53.69M | $767.00K | $37.35M | $16.31M | $28.00K | (m) | 70.00× |
| 2021-06-30 | $57.30M | $876.00K | $41.14M | $16.14M | $28.00K | (m) | 65.42× |
| 2021-03-31 | $63.63M | $970.00K | $48.77M | $14.83M | $34.00K | (m) | 65.60× |
| 2020-12-31 | $54.41M | $1.10M | $38.50M | $15.88M | $34.00K | (m) | 49.38× |
| 2020-09-30 | $54.50M | $795.00K | $38.50M | $15.98M | $26.00K | (m) | 68.56× |
| 2020-06-30 | $40.35M | $833.00K | $33.91M | $6.40M | $46.00K | (m) | 48.45× |
| 2020-03-31 | $31.13M | $703.00K | $27.59M | $3.49M | $46.00K | (m) | 44.27× |
| 2019-12-31 | $8.82M | $1.13M | $1.47M | $7.31M | $44.00K | (m) | 7.83× |
| 2019-09-30 | $11.79M | $4.19M | $9.62M | $2.11M | $62.00K | (m) | 2.81× |
| 2019-06-30 | $2.94M | $1.75M | $959.00K | $1.91M | $76.00K | (m) | 1.68× |
| 2019-03-31 | $4.98M | $2.09M | $2.39M | $2.49M | $101.00K | (m) | 2.39× |
| 2018-12-31 | $2.06M | $5.29M | $299.00K | $1.53M | $235.00K | (m) | 0.39× |
| 2018-09-30 | $4.10M | $4.96M | $4.05M | $20.00K | $28.00K | (m) | 0.83× |
| 2018-06-30 | $4.28M | $2.08M | $3.57M | $674.00K | $35.00K | (m) | 2.06× |
| 2018-03-31 | $4.67M | $2.65M | $3.96M | $682.00K | $29.00K | (m) | 1.76× |
| 2017-12-31 | $2.13M | $2.71M | $1.41M | $695.00K | $24.00K | (m) | 0.79× |
| 2017-09-30 | $2.35M | $2.20M | $503.00K | $1.80M | $42.00K | (m) | 1.07× |
| 2017-06-30 | $3.31M | $2.74M | $1.22M | $1.99M | $98.00K | (m) | 1.21× |
| 2017-03-31 | $3.79M | $2.64M | $776.00K | $2.97M | $41.00K | (m) | 1.44× |
| 2016-12-31 | (m) | $2.44M | $2.41M | $3.46M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $2.43M | $4.47M | $3.54M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $4.43M | $1.54M | $4.97M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $3.09M | $1.01M | $6.84M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $2.43M | $2.12M | $6.79M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $3.33M | $1.16M | $11.21M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $3.10M | $1.84M | $13.87M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $3.82M | $2.94M | $14.06M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $4.44M | $2.16M | $13.95M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $4.26M | $1.26M | $16.17M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $4.16M | $2.62M | $17.59M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $2.99M | $4.11M | $17.45M | (m) | (m) | (m) |
| 2013-12-31 | (m) | $2.53M | $803.00K | $17.39M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $10.63M | $1.60M | $13.55M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $9.86M | $1.31M | $16.84M | (m) | (m) | (m) |
| 2013-03-31 | (m) | $10.03M | $1.59M | $21.41M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $12.65M | $2.21M | $27.24M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $9.79M | $3.16M | $21.90M | (m) | (m) | (m) |
| 2012-06-30 | (m) | $7.36M | $2.17M | $19.44M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $5.98M | $3.65M | $25.47M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $5.07M | $3.10M | $26.23M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $3.60M | $4.02M | $27.70M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $1.95M | $2.08M | $29.53M | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $2.25M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $2.83M | $2.92M | $32.69M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $3.04M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $5.33M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $58.07M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $6.12M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |